Implements Plan to Reduce Annualized Operating Expense Run Rate by $45 Million to $50 Million Q1 2025 Earnings Conference Call Scheduled for May 8, 2025 MENLO PARK, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2025.
Wed, 09 Apr 2025 14:05:00 GMT Our preliminary revenue for ... market uncertainty, PacBio is executing a plan to reduce both headcount across all functions and non-headcount related expenses to lower its annualized non-GAAP ...
Wed, 09 Apr 2025 08:05:00 GMT Implements Plan to Reduce Annualized Operating Expense Run Rate by $45 Million to $50 Million Q1 2025 Earnings Conference Call Scheduled for May ...
Wed, 09 Apr 2025 07:05:00 GMT Our preliminary revenue ... run-rate by $45 million to $50 million by year end in relation to its prior guidance of $270 million to $280 million. Following the reductions, PacBio aims to focus ...
Wed, 09 Apr 2025 07:05:00 GMT Our preliminary revenue ... PacBio. PacBio products are provided for Research Use Only. Not for use in diagnostic procedures. Statement regarding use of non-GAAP financial measures This press ...
